Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sanne Holt"'
Autor:
Gemma Moiset, Sophie Vermond, Monique Hazenoot, Rene McLaughlin, Sabrina de Munnik, Marco Guadagnoli, Sanne Holt, Marijn Vlaming
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d87669392ddd46b18ce37510d23d849f
Publikováno v:
Future Drug Discovery. 2
Immuno-oncology (IO) therapy is an exciting emerging pillar of cancer treatment that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction by either harnessing the effects of the immune system o
Autor:
Gemma Moiset, Julia Schüler, Katharina Schaich, Kanstantsin Lashuk, Sophie Vermond, Sanne Holt, Monique Hazenoot, Eva Oswald
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A150-A150
BackgroundAlthough most breast cancer patients are treated these days with a curative intention, there are still many patients progressing to metastatic disease. The advent of anti-HER2 therapy has prominently prolonged the time of disease progressio
Autor:
Sophie Vermond, Marijn Vlaming, Marco Guadagnoli, Rene McLaughlin, Monique Hazenoot, Sanne Holt
Publikováno v:
Cancer Research. 81:294-294
Cell therapies, such as Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) T cells, are some of the latest immune-therapeutic approaches, showing great momentum in research and now the clinic. Only recently, two anti-CD19-CAR-T products have b
Autor:
Marijn Vlaming, Monique Hazenoot, Sophie Vermond, Rene McLaughlin, Sanne Holt, Marco Guadagnoli
Publikováno v:
Cancer Research. 81:1373-1373
Engineered T cell therapies, such as Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) T cells, but also bi-specific antibody therapies, play a major role in the field of immuno-oncology and offer great promise in becoming a new wave of highl
Autor:
Sanne Holt, Sawsan Youssef, Sophie Vermond, Jake Glanville, Katherine Vousden, Monique Hazenoot, Sarah Ives
Publikováno v:
Cancer Research. 81:922-922
The global market for cell and gene therapies, including T-cell/Natural Killer cell chimeric antigen receptors (CAR-T/NK), is continuing to grow rapidly - with many clinical success stories for B-cell malignancies in particular. However, the path to
Publikováno v:
Cancer Research. 80:3232-3232
Chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered T cells are part of a big wave of immunotherapies showing great promise in cancer clinical trials. With the first T cell based therapies targeting hematological malignances now appr
Publikováno v:
Cancer Research. 80:6705-6705
In order to exploit the complex tumour microenvironment, immunoreactivity in a multitude of cell-based assays is required to predict mode of action (MOA), pharmacodynamics, and efficacy downstream. We have developed an integrated approach starting wi